Newamsterdam pharma announces closing of upsized $479.0 million public offering of ordinary shares and pre-funded warrants, including full exercise of the underwriters' option to purchase additional shares

Naarden, the netherlands and miami, dec. 13, 2024 (globe newswire) -- newamsterdam pharma company n.v. (nasdaq: nams; “newamsterdam” or the “company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“cvd”) with elevated low-density lipoprotein cholesterol (“ldl-c”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritten public offering of (i) 14,667,347 of the company's ordinary shares, nominal value €0.12 per share (the “ordinary shares”), at a public offering price of $24.50 per share, which includes the exercise in full of the underwriters' option to purchase an additional 2,550,000 ordinary shares, and (ii) to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase 4,882,653 ordinary shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.0001 per share exercise price for each such pre-funded warrant (such offering, the “offering”). all of the securities sold in the offering were sold by the company.
NAMS Ratings Summary
NAMS Quant Ranking